NetworkNewsBreaks – NanoViricides (NYSE American: NNVC) Reports Progress in Phase IIA Ebola Treatment Trial of NV-387 Oral Gummies
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, reported progress in its Phase IIA clinical trial evaluating NV-387 Oral Gummies for the treatment of Ebola Bundibugyo virus infection in the Democratic Republic of Congo. The exploratory trial, designed to enroll up to 20 patients with varying disease severity, is assessing the safety and tolerability of treatment regimens ranging from six to 12 days. Although the study is not designed to establish statistically significant efficacy, the company said it may identify preliminary signs of antiviral activity. Following completion of the trial and evaluation of the results, NanoViricides plans to advance an appropriate dosing regimen into an expanded, randomized, controlled Phase IIB study, provided the findings support further development. NV-387 is a broad-spectrum antiviral candidate designed to reduce viral load by targeting host-cell features used by viruses during infection.
To view the full press release, visit https://nnw.fm/9fDB5
NOTE TO INVESTORS: The latest news and updates relating to NNVC are available in the company’s newsroom at https://nnw.fm/NNVC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, reported progress in its Phase IIA clinical trial evaluating NV-387 Oral Gummies for the treatment of Ebola Bundibugyo virus infection in the Democratic Republic of Congo. The exploratory trial, designed to enroll up to 20 patients with varying disease severity, is assessing the safety and tolerability of treatment regimens ranging from six to 12 days. Although the study is not designed to establish statistically significant efficacy, the company said it may identify preliminary signs of antiviral activity. Following completion of the trial and evaluation of the results, NanoViricides plans to advance an appropriate dosing regimen into an expanded, randomized, controlled Phase IIB study, provided the findings support further development. NV-387 is a broad-spectrum antiviral candidate designed to reduce viral load by targeting host-cell features used by viruses during infection.
To view the full press release, visit https://nnw.fm/9fDB5
NOTE TO INVESTORS: The latest news and updates relating to NNVC are available in the company’s newsroom at https://nnw.fm/NNVC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
